SB3曲妥珠单抗生物类似药vs原研新辅助治疗HER2阳性乳腺癌3年随访
这项3期研究的扩展随访评估了HER2阳性早期乳腺癌患者接受SB3或原研曲妥珠单抗(TRZ)后的长期心脏安全性和疗效,中位随访约40.8/40.5个月,无症状显著LVEF下降罕见且无有症状CHF,3年EFS在SB3组为91.9%、TRZ组为85.2%(HR 0.47,95%CI 0.26-0.87),事后分析提示ADCC活性下降可能与EFS差异相关。
要点
- SB3与TRZ长期心脏毒性均罕见,无症状显著LVEF下降少见且均恢复。
- 3年EFS:SB3组91.9%,TRZ组85.2%,HR 0.47(95%CI 0.26-0.87)。
- 事后分析提示ADCC活性下降可能是EFS差异的相关因素。
核心结论
- 扩展研究显示心脏毒性罕见,SB3组EFS高于TRZ组,事后分析提示ADCC活性下降可能是 contributing factor。
研究设计与样本
- 3期研究扩展随访,纳入完成原3期研究的HER2阳性早期乳腺癌患者,SB3组186例、TRZ组181例,共367例。
- 评估有症状CHF、无症状显著LVEF下降、其他心脏事件、EFS和OS,事后用Cox比例风险模型分析EFS相关因素。
主要发现
- 自主要研究入组起中位随访时间SB3组40.8个月、TRZ组40.5个月。
- 辅助治疗后2年随访期间无症状显著LVEF下降罕见(SB3组1例,TRZ组2例),所有患者LVEF恢复至≥50%,无有症状CHF或其他心脏事件报告。
- 3年时EFS在SB3组为91.9%、TRZ组为85.2%;事件数SB3组17例(9.1%)、TRZ组31例(17.1%),HR 0.47(95%CI 0.26-0.87)。
- ADCC活性和乳腺病理完全缓解率是与EFS相关的因素。
关键数值与推荐
- 3年EFS:SB3组91.9%,TRZ组85.2%,HR 0.47(95%CI 0.26-0.87)。
- 无症状显著LVEF下降:SB3组1例,TRZ组2例,均恢复至LVEF≥50%。
- 中位随访:SB3组40.8个月,TRZ组40.5个月。
临床怎么用
- SB3与原研曲妥珠单抗在长期心脏安全性方面均表现良好,支持生物类似药的临床使用。
- EFS数值差异为事后分析,需谨慎解读,不能作为疗效优效性结论。
局限性
- 为扩展研究的事后分析,EFS差异及ADCC活性关联需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We assessed long-term cardiac safety and efficacy in patients with human epidermal growth factor receptor 2-positive early breast cancer treated with a trastuzumab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study. METHODS: Patients who completed the phase 3 study could be enrolled in this extension study. The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymptomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other cardiac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox proportional hazards regression model was used to assess factors associated with EFS. RESULTS: A total of 367 patients were enrolled in the study (SB3, n = 186; TRZ, n = 181). The median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3 and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of asymptomatic significant LVEF decrease was rare (SB3, n = 1; TRZ, n = 2), with all patients recovering with LVEF ≥ 50%, and no cases of symptomatic CHF or other cardiac events were reported. At 3 years, the EFS was 91.9% with SB3 and 85.2% with TRZ. The number of patients with events was 17 (9.1%) with SB3 and 31 (17.1%) with TRZ [hazard ratio: 0.47, 95% confidence interval: 0.26-0.87]. Antibody-dependent cell-mediated cytotoxicity (ADCC) activity and the breast pathologic complete response rate were the factors associated with EFS. CONCLUSION: Cardiotoxicity was rare in this extension study. EFS was higher with SB3 versus TRZ, with post hoc analysis suggesting that a downward drift in ADCC activity was a contributing factor. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02771795 (EudraCT 2015-005663-17).
引用
- Pivot X, Pegram M, Cortes J, et al. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019. PMID: 31445454. doi:10.1016/j.ejca.2019.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。